Ongoing complete response after treatment cessation with dabrafenib, trametinib, and cetuximab as third-line treatment in a patient with advanced BRAFV600E mutated, microsatellite-stable colon cancer: A case report and literature review

Ongoing complete response after treatment cessation with dabrafenib, trametinib, and cetuximab as third-line treatment in a patient with advanced BRAFV600E mutated, microsatellite-stable colon cancer: A case report and literature review

Metastatic BRAFV600E mutated colorectal cancer is associated with poor overall survival and modest effectiveness to standard therapies. Furthermore, survival is influenced by the microsatellite status. Patients with microsatellite-stable and BRAFV600E mutated colorectal cancer have the worst prognos...

Full description

Bibliographic Details
Main Authors: Gudrun Piringer, Jörn Decker, Vera Trommet, Thomas Kühr, Sonja Heibl, Konrad Dörfler, Josef Thaler
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-05-01
Series:Frontiers in Oncology
Subjects:
combination targeted therapy
dabrafenib
trametinib
MSS
BRAF-V600 mutation
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1166545/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1166545/full

Similar Items